Insmed, Inc. (INSM)

Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.

Industry: Pharmaceutical Preparations (SIC 2834)

Market region: US

Address: 700 Us Highway 202/206, Bridgewater, NJ, 08807

Market capitalization

24.70 billion USD (24,697,835,187 USD)

Listing date

06/01/2000

Weighted shares outstanding

219,380,309

Share class shares outstanding

218,381,503

https://www.insmed.com